Technology | December 19, 2011

FDA Clears Berlin Heart's Excor Pediatric Ventricular Assist Device

December 19, 2011— Newborns, toddlers and teens who suffer from heart failure and need heart transplantation to survive just got a life-saving pediatric heart pump that buys time and allows them to grow stronger as they wait for a donor heart. The Berlin Heart Group announced that the U.S. Food and Drug Administration (FDA) has granted Humanitarian Device Exemption (HDE) approval of the Berlin Heart Excor Pediatric ventricular assist device (VAD).

Excor is a mechanical cardiac support system for critically ill pediatric patients suffering from severe heart failure. The system is designed to support pediatric patients of all age groups, from newborns to teenagers, and is intended to bridge patients awaiting heart transplantation from days up to several months, until a donor heart becomes available. Excor, which has previously been approved for use in Europe and Canada, is now the only VAD that is designed specifically for the pediatric population to be approved in the United States.

The national principal investigator for the Excor study, Charles D. Fraser, Jr., M.D., surgeon-in-chief and head of the division of congenital heart surgery at Texas Children’s Hospital and professor of surgery and pediatrics, Baylor College of Medicine in Houston, Texas, said, "On behalf of the many investigators, coordinators and administrative personnel involved in the study, I am extremely gratified by the news that the Excor has achieved an HDE approval by the FDA.  This is a landmark event for children suffering from terminal heart failure. The medical community is now able to offer this lifesaving device to support desperate children who would not otherwise survive while awaiting a heart transplant.  This ushers in a new era for children with heart disease.  The study involved an incredible effort from 15 centers across North American with extensive experience in pediatric heart failure and transplantation and should serve as a model for future collaborative device investigations involving children, industry, medicine, and the FDA."

Study background

In January 2008, Texas Children's was named the national lead center for a 12-hospital, 36-month clinical trial of Excor. Fraser was selected as the national principal investigator (NPI) for the individual device exemption (IDE) prospective study. In 2009, five other hospitals were added to the study.

The Excor pediatric clinical study is the first prospective clinical trial ever conducted to investigate the safety and benefit of a VAD in the pediatric population. Between 2007 and 2010, the study enrolled 48 patients in two cohorts of 24 patients each. Another 200 patients were enrolled in a "compassionate use" cohort.  Along with Texas Children's Hospital, the following U.S. centers participated in the IDE study: Arkansas Children's Hospital (Ark.), Boston Children's Hospital (Mass.), Children's Healthcare of Atlanta (Ga.), Children's Hospital of Wisconsin (Wis.), The Children's Hospital of Denver (Colo.), Lucille Packard Children's Hospital at Stanford (Calif.), Mott Children's Hospital (Mich.), Mount Sinai Hospital (N.Y.), Pittsburgh Children's Hospital (Pa.), Riley Children's Hospital (Ind.), Seattle Children's Hospital (Wash.), St. Louis Children's Hospital (Mo.), Children's Hospital at the University of Alabama at Birmingham (Ala.), and the University of Minnesota at Fairview (Minn.).

As NPI, Fraser worked in cooperation with all 17 hospitals in collecting and reporting data to the FDA regarding the safety and probable benefit of the pediatric heart pump. On July 21, 2011, Fraser led the IDE study team as they presented the final data to an FDA circulatory support advisory panel, which unanimously recommended that the device be approved by the FDA. The final approval came on Dec. 16, 2011.

Texas Children's Heart Center implanted its first Berlin Heart on Sept. 27, 2005, in one of the smallest babies to ever receive the device. Brady Burch, a Corpus Christi resident, is now 6 years old and in kindergarten.  Fraser, who has long advocated that babies need small heart assist devices sized just for them, became proactively involved. He accompanied Berlin Heart representatives to Washington, requesting that the FDA allow an IDE study. The FDA agreed to open a study. The first pediatric patient was enrolled in November 2007.

For more information: www.berlinheart.com

 

Related Content

New Target for Treating Heart Failure Identified by Penn Medicine Researchers

Microtubules in heart cells from a healthy patient (left) and from a patient with heart failure. The dense network of detyrosinated microtubules impedes the motion of the failing heart cell during the heart beat. Credit: Ben Prosser lab, Perelman School of Medicine, University of Pennsylvania

News | Heart Failure | June 25, 2018
New research finds changes in cellular struts called microtubules (MT) can affect the stiffness of diseased human heart...
Gencaro Does Not Reduce Atrial Fibrillation Risk in Heart Failure Patients
News | Heart Failure | May 30, 2018
Data from the GENETIC-AF trial was presented in a “Late Breaking Clinical Trials” oral presentation at the European...
Cardiac Contractility Modulation Safe and Effective as Heart Failure Treatment

Image courtesy of Impulse Dynamics

News | Heart Failure | May 18, 2018
In a new study, cardiac contractility modulation (CCM) therapy was confirmed to significantly improve exercise...
V-Wave Closes $70M Financing to Support Pivotal Study of Heart Failure Therapy
News | Heart Failure | May 16, 2018
Israel-based V-Wave Ltd. recently closed a $70 million Series C financing for its proprietary, minimally invasive...
News | Heart Failure | May 14, 2018
Ancora Heart Inc. announced the expansion of the company’s U.S. feasibility study to evaluate the investigational...
Protein Clumping May Contribute to Heart Failure Development

A PET scan detects clumping proteins in rat hearts (top). The enlarged heart (right) is one with heart failure. Other PET scans showing blood flow in the rat hearts (bottom) show that the protein clumps aren't due to circulation problems. Image courtesy of Circulation Research, May 11, 2018.

News | Heart Failure | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
Minnesota Living With Heart Failure Questionnaire Qualified for FDA Medical Device Development Tools Program

The CORolla device from Israel-based CorAssist is one example of new devices being manufactured and tested to treat heart failure. The efficacy of this and other new devices under development can now be assessed with the Minnesota Living With Heart Failure Questionnaire. 

Technology | Heart Failure | May 07, 2018
The U.S. Food and Drug Administration (FDA) has qualified the Minnesota Living with Heart Failure Questionnaire from...
Nation's First Heart Failure and Arrhythmia Center Opening in Ohio

Image courtesy of The Ohio State University

News | Heart Failure | April 04, 2018
The Ohio State University Wexner Medical Center will establish the nation’s first center dedicated to treating those...
Abbott Initiates GUIDE-HF Trial for Improved Outcomes With CardioMEMS Monitor
News | Heart Failure | March 29, 2018
Abbott announced the company has initiated the landmark GUIDE-HF clinical trial using the CardioMEMS HF System. The...
Overlay Init